You just read:

Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

News provided by

Eli Lilly and Company

Feb 13, 2018, 06:45 EST